For many years, mergers and acquisitions interest in diabetic products and supplies was rather sleepy.

It was a highly competitive business with thin margins and, with all the money in the resupply of test strips, not much of an opportunity to differentiate and create sustainable customer loyalty. So, the big players spent heavily on advertising, cycling patients back and forth between them. They made money. But not the stuff of investor dreams.

But then came the development of affordable continuous glucose monitoring. A technology driven solution to repeated daily pin pricks and endless test strips. A solution that offers continuous monitoring, can integrate with smartphone systems, and provides critical insights as to whether glucose levels are going up, or down, and how fast.

And herein lies the clinical underpinning of why acquisition interest in CGM has fast become a thing in health care mergers and acquisitions.

In addition to demonstrated efficacy, there are other factors that boost acquisition interest in the space.

**CGM monitors are differentiable.** In a presentation to the American Diabetes Association in 2019, one of the presenters compared four systems on nine different features. Among them, implantation method, sensor life, calibration, decision support, and accuracy.¹

Suddenly, patients could find a system they like, and have reason to stick with it.

**CGM offers opportunities for enhanced margins.** More than just a monitoring system, the technology is well suited to be at the center of a comprehensive diabetic management program that can include reminders, on-the-spot education, integration with insulin pumps, communication with caregivers, predictive artificial intelligence and more. Accordingly, not only does CGM do a better job at helping users manage their diabetes, it provides substantial opportunities to develop meaningful competitive advantages, and hence better margins.

But wait, there’s more.

¹ MedCity News; “Quick comparison of Medtronic, Abbott, Dexcom, Senseonics CGMs from ADA 2019,” June 10, 2019
CGM is a fast-growing market. For clinical reasons, CGM became the standard of care for Type 1 diabetes in 2016. But “high costs and uncertainty over efficacy and necessity have kept CGM from widespread use in people with T2D.” But recently, “the newest CGM models... have begun to overcome many of these technical barriers to use of CGM systems.” And according to the CDC, “more than 34 million Americans have diabetes (about 1 in 10), and approximately 90-95% of them have type 2 diabetes.” Talk about growth opportunity.

It’s an annuity. Currently there is no cure for diabetes. So, companies that stay on top of the latest technology and provide value-added customer support and education can enjoy long term and sustainable revenue streams that propel growth and reduce risk, which, together drives up valuation.

Size really does matter. If a provider can grow large enough to purchase monitors and supplies directly from manufacturers versus distributors – thereby reducing their cost of goods sold – they can pick up an additional 10-12% of profit margin. This creates enormous incentives to grow quickly through acquisition. What’s more, if placed in a competitive auction to acquire a target, buyers could have equally enormous incentives to offer extraordinary premiums to drive the cost of goods down for their entire operation.

The Consolidation Play

So, who’s buying – or should be?

Private Equity. Well, given its narrow focus, opportunities to leverage technology and logistics to drive down costs, and clear pathway to growth, increased profitability, and value, CGM is a near perfect roll-up play for private equity.

Traditional HME providers. It’s also a natural product line extension for the existing large players in the home medical equipment and respiratory market. With AdaptHealth’s successful initial public offering, and the recent announcement of a pending IPO for Apria, should Linde seek a similar opportunity for Lincare, we may very well see an all-out brawl for size, market share, and growth, reminiscent of the late 90s and early 2000s – all of which could be fed substantially with CGM.

CPAP providers. Given their experience in customer acquisition, retention, and re-supply, we also see CGM as an excellent product line extension for those companies that focus primarily on CPAP products and supplies.

The Punchline

So, what does this all mean if you are a growing provider of CGM? Undoubtedly, most if not all of you have been contacted by at least one or two potential acquirers from the group above. That’s what happens when there is a sudden groundswell of interest in a space. Perhaps the most important takeaway then is that there are far more buyers out there then the “usual suspects” – and more likely to come.

Accordingly, to maximize value and surface the greatest premium the market will allow, there is simply no short-cut to pursuing a pro-active, strategically orchestrated auction process with multiple buyers competing for your business at the same time. Only then will buyers be “forced” to fully consider all the synergies and supply vs. demand, market timing, purchasing power, and other factors and intangibles to determine just how much of a premium they would be willing to pay to complete a transaction. Wink, wink.

---

2 AJMC; “A New Era: Increasing Continuous Glucose Monitoring Use in Type 2 Diabetes;” March 31, 2019
3 Ibid
4 CDC; Type 2 Diabetes: https://www.cdc.gov/diabetes/basics/type2.html
INSIGHT INTO HEALTH CARE SERVICES MERGERS & ACQUISITIONS

THE BRAFF GROUP INDUSTRY EXPERTS

Dexter Braff  
President  
Pittsburgh

Pat Clifford  
Managing Director  
HME & Pharmacy  
Chicago  
888-922-1834  
pclifford@thebraffgroup.com

Steve Garbon  
Director of Finance  
Pittsburgh  
412-833-8690  
sarbon@thebraffgroup.com

THE BRAFF GROUP INDUSTRY EXPERTS

Dexter Braff  
President  
Pittsburgh

Pat Clifford  
Managing Director  
HME & Pharmacy  
Chicago  
888-922-1834  
pclifford@thebraffgroup.com

Steve Garbon  
Director of Finance  
Pittsburgh  
412-833-8690  
sarbon@thebraffgroup.com

20 YEARS & COUNTING

The Braff Group is the leading mergers and acquisitions advisory firm specializing exclusively in health care services, including behavioral health, digital health, home health and hospice, pharmacy services, urgent care, health care staffing, home medical equipment and ancillary health care services. The firm provides an array of sell-side only transaction advisory services including representation, debt and equity recapitalization, strategic planning, and valuation. Founded in 1998, The Braff Group has completed more than 345 transactions. According to Refinitiv, The Braff Group has repeatedly been ranked among the top 5 health care mergers & acquisitions advisory firms.

• Behavioral Health  • Home Health & Hospice  • Pharmacy Services  • Urgent Care
• Digital Health  • Home Medical Equipment  • Staffing  • Ancillary Services

The Braff Group  
1665 Washington Road, Suites 3 & 4  
Pittsburgh, Pennsylvania  15228  
888.922.5169  
thebraffgroup.com